|
|
 | | | |
- close
- close
- close
- close
The Australian
Apr 24
Comment
PHARMAXIS will push on with plans to have its drug Bronchitol approved to treat a lung disorder despite disappointing trials.
The Australian
Apr 24
Comment
PHARMAXIS stock plunged more than 40pc after the drug firm said a late-stage trial of its bronchiectasis medicine had disappointed.
Sydney Morning Herald
Apr 22
Comment
Drug developer Pharmaxis shares are in a trading halt while it evaluates results from a late-stage trial of its drug to treat bronchiectasis.
FierceBiotech
Mar 19
Comment
Pharmaxis has been dealt another blow by the FDA. The Australian company confirmed Tuesday morning that the regulatory agency has rejected its bid to market the cystic fibrosis drug Bronchitol for treatment in U.S. patients.
The FDA reviewed...
FierceBiotech
Mar 12
Comment
Facing down a recent FDA advisory committee vote against Bronchitol, Australia's Pharmaxis says that it has found a new CEO and is reviewing its business strategy. Dr. Alan Robertson has left the company and is being replaced by COO Gary Phillips,...
Sydney Morning Herald
Mar 12
Comment
Pharmaxis has replaced its chief executive and is set to review its business model, the Australian drug maker says.
Sydney Morning Herald
Feb 14
Comment
Australian drug maker Pharmaxis has reported a $20.8 million net loss for the six months to December, a 6 per cent increase in net loss from the previous corresponding period.
FierceBiotech
Jan 31
Comment
At the same time Australian Pharmaxis inks a financing deal with NovaQuest Pharma Opportunities Fund III for up to $40 million, the company has gotten disappointing news from the FDA--its cystic fibrosis (CF) inhalant therapy received a negative...
FierceBiotech
Jan 31
Comment
An FDA advisory committee handed Pharmaxis a major setback in its quest to get a new cystic fibrosis treatment onto the U.S. market, voting that the Australian biotech couldn't prove Bronchitol was safe and effective. The news swiftly crushed its...
The Australian
Jan 31
Comment
SHARES in Pharmaxis plummeted more than 45pc after a US committee rejected an application for its cystic fibrosis drug.
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
